GENENTECH, INC.

COLUMVI

ASP | WAC | AWP at the HCPCS Unit

Manufacturer:

GENENTECH, INC.

Columvi HCPCS:

J9286

HCPCS Code Descriptor:

Injection, glofitamab-gxbm, 2.5 mg

Category:

J Code

Columvi NDCs:

50242-0127-01, 50242-0125-01

Primary Type:

Oncology

Generic/Specialty Status:

Single-Source

Package Type:

Vial

Route of Administration:

Intravenous

Columvi CPT Codes:

-96413 - Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug

-96415 - Chemotherapy administration, intravenous infusion technique; each additional hour (List separately in addition to code for primary procedure)

Some of the most common CPT administration codes for 'buy and bill' drugs can be found at the following link:

Potential NDC Listing Errors:

We have not identified any potential errors with the NDCs mapped to this HCPCS code.

About Columvi:

COLUMVI is a Oncology drug manufactured by GENENTECH, INC. and administered via the Intravenous route of administration. The J Code: J9286 is aligned to the drug COLUMVI.

Columvi is an immunotherapy drug used that is often used to treat treatment-resistant or recurring diffuse large B-cell lymphoma (DLBCL). DLBCL is an aggressive form of non-Hodgkin’s lymphoma, and is one of the most prevalent types of blood cancer in adults. Columvi works by binding certain proteins in the body together and acting as a bridge between cancer cells and your immune system's T cells.

ACCESS PRICING AND MORE BY REGISTERING

J9286 Added Date:

January 1, 2024

J9286 Effective Date:

January 1, 2024

J9286 Termination Date:

HCPCS Active

View a Columvi billing and coding guide at the link below:
Columvi patient assistance information can be found through Genentech at the URL: https://www.columvi.com/financial-support/assistance-options.html
COLUMVI prescribing information can be found at the link below:
Information regarding COLUMVI’s side effects can be found at MedlinePlus